Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma

Por Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, Kleinclauss F, Pivot X, Limat S, Thiery-Vuillemin A
Publicado em 2014-02-01

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study

Por Royer, B, Kalbacher, E, Onteniente, S, Jullien, V, Montange, D, Piedoux, S, Thiery-Vuillemin, A, Delroeux, D, Pili-Floury, S, Guardiola, E, Combe, M, Muret, P, Nerich, V, Heyd, B, Chauffert, B, Kantelip, J-P, Pivot, X
Publicado em 2012

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a rand...

Por Gaiffe, E., Crepin, T., Bamoulid, J., Courivaud, C., Büchler, M., Cassuto, E., Albano, L., Chemouny, J. M., Choukroun, G., Hazzan, M., Kessler, L., Legendre, C., Le Meur, Y., Ouali, N., Thierry, A., Anota, A., Nerich, V., Limat, S., Bonnetain, F., Vernerey, D., Ducloux, D.
Publicado no Trials (2019)